Investment Firm Coinvest Capital Supports Psylink's cutting-edge biotechnology for mental health care
Psylink, a Lithuanian deep-tech biotechnology company, is making waves in the mental healthcare market with its innovative strategy to develop science-driven treatments for mental health disorders. The company's approach, which bridges traditional wisdom and modern neuroscience, is seen as a transformative innovation that the mental healthcare market urgently needs [1].
At the heart of Psylink's strategy is a sustainable biotechnology platform that uses engineered yeast cells to produce plant- and fungi-derived compounds. This eco-friendly approach offers a scalable, cost-efficient, and environmentally friendly alternative to traditional chemical synthesis and extraction [2].
The company operates at the intersection of biotechnology, neuroscience, and natural product discovery. Psylink's primary focus is on the discovery and evaluation of novel therapeutic compounds for conditions such as depression and PTSD, particularly for the 30–40% of patients who do not respond to conventional antidepressants [3].
Erin Gainer, leading the angel investor syndicate, expresses optimism about Psylink's potential to significantly transform treatment possibilities for mental health issues. She is joined by venture capital fund Coinvest Capital, Firstpick, and BSV Ventures, who have all invested in Psylink's pre-seed round [4].
Sandra Golbreich, Partner at BSV Ventures, praises Psylink as a rare example of deep-tech innovation from the region, addressing a global issue with a strong scientific foundation and a clear mission [5].
Psylink's approach of combining rigorous biotechnology with the therapeutic potential of natural compounds is praised as innovative and grounded in strong scientific validation. The capital raised will be used to advance Psylink's proprietary biotechnology platform for the sustainable production of plant- and fungi-derived compounds. It will also fund the screening and evaluation of novel molecular candidates, speeding up the identification of high-potential compounds for further development and preclinical validation [1].
Laura Korsakova, CEO of Psylink, leads a multidisciplinary team committed to safe, effective, and scalable mental health solutions. The team is focused on studying psilocybin and related fungal metabolites to uncover new treatment candidates [2].
In summary, Psylink’s progress and innovation strategy involve:
- Developing a sustainable biotech platform using engineered yeast to produce bioactive plant- and fungi-derived compounds at scale, minimizing environmental impact.
- Conducting molecular-level research to discover and optimize novel psychedelic derivatives that precisely target serotonin receptors implicated in mental health disorders.
- Targeting treatment-resistant patients by creating new therapeutic options based on natural compounds like psilocybin.
- Leveraging recent funding to enhance production capabilities and accelerate candidate screening for clinical development.
This integrated approach combines synthetic biology with neuroscience and natural product discovery to innovate next-generation mental health therapies with sustainability at the core [1][2][3].
Sandra Golbreich expresses BSV Ventures' pride in supporting a team developing real biotech with the potential to transform how mental health is treated. Psylink aims to fill a critical gap in the mental healthcare market, focusing on patients who do not respond to conventional therapies [5].
[1] https://www.psylink.eu/ [2] https://www.psychreg.org/psylink-developing-innovative-sustainable-biotech-platform-mental-health-treatments/ [3] https://www.tech.eu/news/lithuanian-startup-psylink-raises-500k-to-develop-sustainable-biotech-platform-for-psychedelic-drugs/ [4] https://www.baltic-venture.com/news/bsv-ventures-leads-pre-seed-round-in-lithuanian-startup-psylink/ [5] https://www.baltic-venture.com/news/psylink-raises-500k-to-develop-sustainable-biotech-platform-for-psychedelic-drugs/
- Psylink, a Lithuanian deep-tech biotechnology company, is utilizing science and technology to innovate sustainably-produced mental health therapies and treatments, focusing on conditions like depression and PTSD.
- Erin Gainer, along with investors like Coinvest Capital, Firstpick, and BSV Ventures, believes that Psylink's approach, which combines neuroscience, biotechnology, and natural product discovery, has the potential to significantly transform mental health care.
- In the health-and-wellness sector, Psylink is bridging the gap in the mental healthcare market by developing science-driven therapies-and-treatments, particularly for patients who do not respond to conventional antidepressants, leveraging the therapeutic potential of natural compounds such as psilocybin.
